A Phase 3 interventional study of SPK-8011 in Hemophilia A, sponsored by Spark Therapeutics, Inc.. Withdrawn at 27 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-13.
Sponsored by Spark Therapeutics, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Hemophilia A by Hoffmann-La Roche — 5 open to participants now, 8 under way, 4 of them phase 3. Hemophilia A · Hoffmann-La Roche.
Among the 25 studies in Hemophilia A by Hoffmann-La Roche, this one is the 20th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2024, is one of 12 in phase 3, and was the 21st registered.
845 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.
Browse Hemophilia A studies →5 of the 25 studies in Hemophilia A by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Japan
Ages 0–17
Hoffmann-La Roche · Sites in United States
Ages 18+ · Men only
Hoffmann-La Roche · Sites in United States, Argentina, Austria and 15 more countries
Ages 12+
Hoffmann-La Roche · Sites in United States, Argentina, Australia and 19 more countries
Ages 12+
Hoffmann-La Roche · Sites in United States, Canada, Italy and 3 more countries
Ages 2–59 · Men only
By country, each count listing its studies:
Of the 88 Hemophilia A studies recruiting now, 52 (59%) set no upper age limit and 31 (35%) stop at 75 or younger; 56 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 4 · Phase 3 12 · Phase 4 2
First in 2012; this study’s year is marked. 1 started in 2024.
Median enrollment 58 across the 20 interventional studies, 66 across the 4 observational. Of the 15 that completed or were terminated, 12 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Spark Therapeutics, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Spark Therapeutics, Inc. is the lead sponsor of 14 studies on the registry; none are open to participants now.
1 of the studies in Hemophilia A by Hoffmann-La Roche that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07416526Phase 3Hoffmann-La RocheA Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A | 2027-09-23 |
Add it to your calendar (.ics) → With an account.
Among the 25 studies in Hemophilia A by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of SPK-8011 in preventing bleed episodes compared with FVIII prophylaxis in participants with hemophilia A without FVIII inhibitors on routine FVIII prophylaxis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Meet the following inclusion criteria by cohort:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with severe or moderately severe hemophilia A without FVIII inhibitors using routine FVIII prophylaxis
Genetic: SPK-8011
Participants with severe or moderately severe hemophilia A without FVIII inhibitors using on-demand FVIII replacement therapy
Genetic: SPK-8011
Participants with severe or moderately severe hemophilia A without FVIII inhibitors using emicizumab prophylaxis
Genetic: SPK-8011
Participants will receive a single dose of SPK-8011, administered by intravenous (IV) infusion, on Day 1.
Also known as: AAV-Spark200-BDD-hFVIII, Dirloctocogene samoparvovec
Annualized Bleed Rate (ABR) for All Bleeds [Cohort A]
Time frame: Up to 66 weeks post-SPK-8011 infusion
Median FVIII: C levels [Cohort A]
Time frame: Up to approximately 10 years
ABR for treated bleeds [Cohort A]
Time frame: Up to approximately 10 years
Percentage of Participants with ABR=0 for all bleeds; treated bleeds; treated spontaneous bleeds; and treated joint and target joint bleeds [Cohort A]
Time frame: Up to approximately 10 years
ABR for treated spontaneous, joint, and target joint bleeds [Cohort A]
Time frame: Up to approximately 10 years
Annualized FVIII dosage [Cohort A]
Time frame: Up to approximately 10 years
Proportion of Resolved Target Joints [Cohort A]
Time frame: Up to approximately 10 years
Mean Change of Total Hemophilia Joint Health Score [Cohort A]
Time frame: Baseline, up to 66 weeks post-SPK-8011 infusion
FVIII:C levels over time [Cohort A]
Time frame: Up to approximately 10 years
Mean ABR for all bleeds and treated bleeds [Cohort C]
Time frame: Up to approximately 10 years
FVIII: C levels over time from Week 26 [Cohort C]
Time frame: Up to approximately 10 years
Proportion of Participants Who Receive IV Methylprednisolone (IVMP) Prior to Week 8 (Early IVMP) [Cohorts A, B, C]
Time frame: Up to approximately 10 years
Proportion of Participants Who Receive Secondary Oral Immunomodulation [Cohorts A, B, C]
Time frame: Up to approximately 10 years
Median Time to First Immunomodulation-related Corticosteroid Dose [Cohorts A, B, C]
Time frame: Up to approximately 10 years
Median Duration of Secondary Oral Immunomodulation [Cohorts A, B, C]
Time frame: Up to approximately 10 years
Proportion of Participants with FVIII Inhibitor Development [Cohorts A, B, C]
Time frame: Up to approximately 10 years
Proportion of participants with Treatment-related AEs of ALT Elevation [Cohorts A, B, C]
Time frame: Up to approximately 10 years
Proportion of participants with treatment-related AEs of Infusion Reaction [Cohorts A, B, C]
Time frame: Up to approximately 10 years
Number of participants with abnormal physical exam findings, abnormal vital signs, and abnormal selected clinical laboratory test results [Cohorts A, B, C]
Time frame: Up to approximately 10 years
Proportion of participants with AEs and SAEs [Cohorts A, B, C]
Time frame: Up to approximately 10 years
Proportion of participants with AESIs [Cohorts A, B, C]
Time frame: Up to approximately 10 years
Started Mar 2024 (actual). Primary completion is estimated for May 2027, 38 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.